Review



mouse svegf r1 sflt 1 elisa kit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems mouse svegf r1 sflt 1 elisa kit
    Mouse Svegf R1 Sflt 1 Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/neutralizing+antibodies+against+sflt-1/Mouse+sVEGFR1%2FFlt-1+DuoSet+ELISA/pmc03543655-110-8-16
    Average 94 stars, based on 24 article reviews
    mouse svegf r1 sflt 1 elisa kit - by Bioz Stars, 2026-09
    94/100 stars

    Images

    Related Articles

    Clinical Proteomics:

    Article Title: Low dose aspirin prevents endothelial dysfunction in the aorta and foetal loss in pregnant mice infected with influenza A virus
    Article Snippet: .. Circulating levels of FLT-1 in plasma samples were quantified with a commercially available sFLT-1 ELISA kit as per manufacturer’s instructions (cat# DY471, R&D Systems). ..

    Article Title: Mouse fetal growth restriction through parental and fetal immune gene variation and intercellular communications cascade
    Article Snippet: Cells were then harvested using Accutase cell dissociation reagent (Fisher Scientific) after 24 h and stained as per the flow cytometric staining protocol. .. Mouse VEGF R1/Flt-1 (R&D systems), PIGF-2 (R&D systems) and Endoglin/CD105 (R&D systems) were measured in plasma samples collected from pregnant mice on gd18.5. ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Low dose aspirin prevents endothelial dysfunction in the aorta and foetal loss in pregnant mice infected with influenza A virus
    Article Snippet: .. Circulating levels of FLT-1 in plasma samples were quantified with a commercially available sFLT-1 ELISA kit as per manufacturer’s instructions (cat# DY471, R&D Systems). ..

    Article Title: The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health
    Article Snippet: .. Concentrations of soluble fms-like tyrosine kinase 1 (sFLT-1), endothelin-1 (ET-1), and C-reactive protein (CRP) in maternal serum were measured using the Mouse sVEGFR1/Flt-1 DuoSet ELISA kit (samples diluted 1:100), Mouse Endothelin-1 Quantikine ELISA Kit (sensitivity 0.207 pg/ml), and Mouse C-Reactive Protein/CRP Quantikine ELISA Kit (sensitivity 0.015 ng/ml) (R&D Systems), respectively, according to the manufacturer’s instructions (inter and intra assay coefficients of variation under 10%). .. Albumin and creatinine concentrations in urine were measured using the Mouse Albumin ELISA kit (sensitivity 5 ng/ml) and Mouse Creatinine Kit (80630, 80350; Crystal Chem) run according to manufacturer’s instructions.

    Article Title: Actions of Esomeprazole on the Maternal Vasculature in Lean and Obese Pregnant Mice with Impaired Nitric Oxide Synthesis: A Model of Preeclampsia
    Article Snippet: .. Concentrations of soluble fms-like tyrosine kinase 1 (sFLT-1), endothelin-1 (ET-1), and C-Reactive Protein (CRP) in maternal serum were measured using the Mouse sVEGFR1/Flt-1 DuoSet ELISA kit (samples diluted 1:100), Mouse Endothelin-1 Quantikine ELISA Kit, and Mouse C-Reactive Protein/CRP Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) respectively, according to the manufacturer’s instructions. .. RNA was extracted from kidneys using RNAeasy Total RNA extraction kit (Qiagen, Valencia, CA, USA) and quantified with a Nanodrop 2000 spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA).

    Article Title: Assisted reproductive technologies induce temporally specific placental defects and the preeclampsia risk marker sFLT1 in mouse
    Article Snippet: .. Serum was diluted 1:25 and ELISA was performed in duplicate by individuals blinded to experimental group using Mouse sVEGFR1/FLT1 DuoSet ELISA and DuoSet ELISA Ancillary Reagent Kit 2 (DY471, DY008, R&D Systems) according to manufacturer's instructions. ..

    Intra Assay:

    Article Title: The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health
    Article Snippet: .. Concentrations of soluble fms-like tyrosine kinase 1 (sFLT-1), endothelin-1 (ET-1), and C-reactive protein (CRP) in maternal serum were measured using the Mouse sVEGFR1/Flt-1 DuoSet ELISA kit (samples diluted 1:100), Mouse Endothelin-1 Quantikine ELISA Kit (sensitivity 0.207 pg/ml), and Mouse C-Reactive Protein/CRP Quantikine ELISA Kit (sensitivity 0.015 ng/ml) (R&D Systems), respectively, according to the manufacturer’s instructions (inter and intra assay coefficients of variation under 10%). .. Albumin and creatinine concentrations in urine were measured using the Mouse Albumin ELISA kit (sensitivity 5 ng/ml) and Mouse Creatinine Kit (80630, 80350; Crystal Chem) run according to manufacturer’s instructions.



    Similar Products

    neutralizing antibodies against sflt-1  (R&D Systems)
    90
    R&D Systems neutralizing antibodies against sflt-1
    Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and <t>sFlt-1</t> in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.
    Neutralizing Antibodies Against Sflt 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/neutralizing+antibodies+against+sflt-1/vegf+elisa+kit/pmc06886281-71-30-35
    Average 90 stars, based on 1 article reviews
    neutralizing antibodies against sflt-1 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and sFlt-1 in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.

    Journal: Journal of Tissue Engineering

    Article Title: Construction of a vascularized bladder with autologous adipose-derived stromal vascular fraction cells combined with bladder acellular matrix via tissue engineering

    doi: 10.1177/2041731419891256

    Figure Lengend Snippet: Exogenous recombinant Wnt5a mediates SVFs vascular self-assembly. SVFs were treated with increasing concentrations of recombinant Wnt5a: (a and b) The effects of various concentrations of recombinant Wnt5a on neovascularization in Matrigel plugs. After stimulation with different concentrations of recombinant Wnt5a, the plugs were removed on day 14 after Matrigel injection for the visualization and quantification of angiogenesis. Representative photographs of plugs from groups of five animals are shown. Quantification of angiogenesis within the Matrigel plugs is shown for all conditions. (c and d) During stimulation with different concentrations of Wnt5a, the expression of the vascularization-stimulating factors MMP2, MMP9, VEGFR2, and sFlt-1 in SVFs gradually increased. (e and f) At 4 weeks, the expression of Wnt5a and the vascular inhibitor sFlt-1 in the SVF-BAM group simultaneously increased. *p < 0.05; **p < 0.01; ***p < 0.005.

    Article Snippet: Briefly, 2.5 × 10 5 SVFs were treated with five different concentrations of recombinant human Wnt5a (0, 10, 50, 100, and 200 ng/mL; R&D Systems, Minneapolis, MN, USA) or neutralizing antibodies against sFlt-1 (10 µg/mL; R&D Systems) premixed with Matrigel (1 mg/mL) and EGM-2, and injected subcutaneously into nude mice in both inguinal regions.

    Techniques: Recombinant, Injection, Expressing

    sFlt-1 suppresses the angiogenesis of SVFs: (a) Tube formation assays in SVFs treated with sFlt-1 neutralizing antibody, magnification ×40 and (b) Matrigel plug angiogenesis assay in SVFs treated with sFlt-1 neutralizing antibody. **p < 0.01.

    Journal: Journal of Tissue Engineering

    Article Title: Construction of a vascularized bladder with autologous adipose-derived stromal vascular fraction cells combined with bladder acellular matrix via tissue engineering

    doi: 10.1177/2041731419891256

    Figure Lengend Snippet: sFlt-1 suppresses the angiogenesis of SVFs: (a) Tube formation assays in SVFs treated with sFlt-1 neutralizing antibody, magnification ×40 and (b) Matrigel plug angiogenesis assay in SVFs treated with sFlt-1 neutralizing antibody. **p < 0.01.

    Article Snippet: Briefly, 2.5 × 10 5 SVFs were treated with five different concentrations of recombinant human Wnt5a (0, 10, 50, 100, and 200 ng/mL; R&D Systems, Minneapolis, MN, USA) or neutralizing antibodies against sFlt-1 (10 µg/mL; R&D Systems) premixed with Matrigel (1 mg/mL) and EGM-2, and injected subcutaneously into nude mice in both inguinal regions.

    Techniques: Angiogenesis Assay